<DOC>
	<DOC>NCT01340040</DOC>
	<brief_summary>The primary purpose of this study is to explore the safety and tolerability of MEDI-573 in Japanese subjects with advanced solid tumours refractory to standard therapy or for which no standard therapy exists.</brief_summary>
	<brief_title>Dose-escalation Study to Assess Safety, Tolerability and Pharmacokinetics of MEDI-573 in Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Japanese men or women at least 20 years of age Histological or cytological confirmation of a solid, malignant tumour excluding lymphoma that is refractory to standard therapies or for which no standard therapies exist WHO performance status 02 with no deterioration over the previous 2 weeks Previous therapy with medication against IGF (ie, monoclonal antibodies with IGF1R or IGFtargeting tyrosine kinase inhibitors) Inadequate bone marrow reserve or organ function Poorly controlled diabetes mellitus as defined by the investigator's assessment and/or glycosylated hemoglobin (HbA1c) reading &gt; 6.5% within 28 days prior to the first dose of MEDI573 History of allergy or reaction to any component of the MEDI573 formulation or drugs with a similar chemical structure or class to MEDI573</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>solid tumours</keyword>
	<keyword>advanced solid malignancies</keyword>
	<keyword>dose escalation</keyword>
	<keyword>Insulin like growth factor</keyword>
	<keyword>Japanese</keyword>
</DOC>